| Product Name | Acalabrutinib - API |
| Product Code | DA-A013-16 |
| Chemical name | Acalabrutinib |
| Synonyms | 4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide; (S)-4-(8-Amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide; (S)-4-[8-Amino-3-[1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(pyridin-2-yl)benzamide; Calquence; |
| Impurity | NA |
| CAS Number | 1420477-60-6 |
| Alternate CAS # | NA |
| Molecular form | C26H23N7O2 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 465.52 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | intermediates,pharmaceutical standards,Fine Chemicals |
| Boiling Point | NA |
| Applications | Acalabrutinib is a Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. acalabrutinib has been used in trials studying the treatment of B-All, Myelofibrosis, Ovarian Cancer, Multiple Myeloma, and Hodgkin Lymphoma, among others.This Bruton Tyrosine Kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle Cell Lymphoma (MCL) who have already received at least one prior therapy. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
